Assessment of suicidal ideation and behavior in clinical trials: challenges and controversies

Glenn Alexander Melvin, Michael Solomon Gordon, Belinda Freake

Research output: Contribution to journalArticleOther

Abstract

The association between several psychoactive medications and suicidal adverse events, as well as the recent focus on treatment of suicidal behaviors, has resulted in increased attention on the assessment of suicidal ideation and behavior within clinical trials. Measurement of suicidal adverse events is now required in clinical trials of a range of medications. The Columbia Suicide Severity Rating Scale is the leading measure of suicidal adverse events. It is brief, measures both suicidal ideation and behavior, contains definitions of each term and has promising psychometric properties
Original languageEnglish
Pages (from-to)265 - 273
Number of pages9
JournalClinical Investigation
Volume2
Issue number3
DOIs
Publication statusPublished - 2012

Cite this